Background: Correct diagnosis of maturity-onset diabetes of the young (MODY), which
is often misdiagnosed as Type 1 or 2 diabetes, is important for providing appropriate
treatment. Materials & Methods: A diabetes model was adapted to Hungary, the Netherlands,
and the UK to analyse the cost-effectiveness and budget impact of different screening
strategies for MODY with 20 years time horizon. Results: Compared with no screening,
screening with the MODY calculator then genetic testing is considered cost-effective
with respect to each country's willingness to pay threshold. The addition of autoantibody
testing dominated the no screening strategy. The budget impact of the strategies ranges
between 0.001 and 0.025% of annual public healthcare spending. Conclusion: The analysed
strategies are considered good value for money with potential cost savings in the
long term.
